Anoro Ellipta Side Effects

Generic Name: umeclidinium / vilanterol

Note: This page contains information about the side effects of umeclidinium / vilanterol. Some of the dosage forms included on this document may not apply to the brand name Anoro Ellipta.

Not all side effects for Anoro Ellipta may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to umeclidinium / vilanterol: inhalation powder

In addition to its needed effects, some unwanted effects may be caused by umeclidinium / vilanterol. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking umeclidinium / vilanterol:

Less common
  • Body aches or pain
  • chest pain
  • congestion
  • cough
  • dryness or soreness of the throat
  • fever
  • headache
  • hoarseness
  • pain or tenderness around the eyes and cheekbones
  • stuffy or runny nose
  • tender, swollen glands in the neck
  • tightness of the chest
  • trouble breathing
  • trouble swallowing
  • voice changes
Rare
  • Chest discomfort
  • dizziness
  • fainting
  • fast or irregular heartbeat
  • nausea
  • pain or discomfort in the arms, jaw, back, or neck
  • sweating
  • vomiting

Some of the side effects that can occur with umeclidinium / vilanterol may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Diarrhea
  • difficulty having a bowel movement (stool)
  • muscle spasms
Rare
  • Acid or sour stomach
  • belching
  • burning, dry, or itching eyes
  • discharge or excessive tearing
  • dry mouth
  • heartburn
  • indigestion
  • lack or loss of strength
  • rash or itching skin
  • redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
  • stomach discomfort, upset, or pain

For Healthcare Professionals

Applies to umeclidinium / vilanterol: inhalation powder

General

The most common adverse reaction was nasopharyngitis (9%).[Ref]

Endocrine

Common (1% to 10%): Diabetes Mellitus[Ref]

Gastrointestinal

Common (1% to 10%): Constipation, dry mouth, diarrhea, nausea, abdominal pain, toothache
Uncommon (0.1% to 1%): Dyspepsia, gastroesophageal reflux disease, vomiting[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection
Frequency not reported: Signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination)[Ref]

Musculoskeletal

Common (1% to 10%): Pain in extremity, muscle spasms, neck pain, back pain, arthralgia
Uncommon (0.1% to 1%): Musculoskeletal chest pain[Ref]

Nervous system

Common (1% to 10%): Headache[Ref]

Other

Common (1% to 10%): Vertigo
Uncommon (0.1% to 1%): Asthenia[Ref]

Respiratory

Common (1% to 10%): Pharyngitis, sinusitis, nasopharyngitis, lower respiratory tract infection, upper respiratory tract infections, cough, chest pain, pleuritic pain, viral respiratory tract infection, oropharyngeal pain
Uncommon (0.1% to 1%): Productive cough, chest discomfort
Frequency not reported: Paradoxical bronchospasm[Ref]

Cardiovascular

Uncommon (0.1% to 1%): Atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, rhythm idioventricular, tachycardia, supraventricular tachycardia
Frequency not reported: Symptoms of increases in pulse rate, systolic or diastolic blood pressure[Ref]

Dermatologic

Uncommon (0.1% to 1%): Pruritus, rash[Ref]

Ocular

Uncommon (0.1% to 1%): Conjunctivitis
Frequency not reported: Worsening of narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema)[Ref]

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.

3. Kelleher DL, Mehta RS, Jean-Francois BM, et al. "Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial." PLoS One 7 (2012): e50716

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)